On Apr. 17, 2020, as part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved Seagen’s…
On Dec. 20, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Daiichi Sankyo’s Enhertu…
On Dec. 3, 2019, the Cold Spring Harbor Laboratory researchers with colleagues at UConn Health and Jackson Laboratory…
On Aug. 15, 2019, Masonic Cancer Center researchers Reuben Harris, PhD and Douglas Yee, MD announced that they…
On Feb. 28, 2019, the U.S. Food and Drug Administration (FDA) approved trastuzumab and hyaluronidase-oysk injection,for subcutaneous use…
On Jan. 21, 2019, researchers at Fred Hutchinson Cancer Research Center announced finding a way to essentially smother…
On Jun. 3, 2018, findings were reported from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or…
On Mar. 9, 2018, Seattle Genetics announced it had completed its acquisition of Cascadian Therapeutics for approximately $614…
On Mar. 6, 2018, the U.S. Food and Drug Administration authorized 23andMe’s Personal Genome Service Genetic Health Risk…
On Jul. 17, 2006, the SERM drug raloxifene (Evista) was found to reduce breast cancer risk for postmenopausal…
On Jan. 11, 2016, the U.S. Preventive Services Task Force (USPSTF) recommended biennial screening mammography for women aged…
On Jul. 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, a privately held biotechnology company…
On Feb. 22, 2013, the U.S. Food and Drug Administration (FDA) announced they had approved Genentech’s licensed ado-trastuzumab…
On Jun. 8, 2012, the U.S. Food and Drug Administration (FDA) announced that Genentech’s drug Perjeta (pertuzumab) was…
On May 13, 2008, the U.S. Congress passed the Breast Cancer and Environmental Research Act which amended the…
On Apr. 29, 2008, National Cancer Institute (NCI) researchers identified a pattern of gene activity in mice that…
In 2008, the Seattle Cancer Care Alliance introduced the Mammovan, making digital mammography more accessible to women throughout…
On Dec. 12, 2007, the Breast Cancer Research Stamp Reauthorization Act extended through Dec. 31, 2011, provisions requiring…
On Nov. 27, 2007, a new National Cancer Institute (NCI) model for calculating invasive breast cancer risk, called…
On Apr. 20, 2007, the National Breast and Cervical Cancer Early Detection Program Reauthorization Act of 2007 allowed…
On Apr. 18, 2007, a study led by the University of Texas M.D. Anderson Cancer Center reported that…
On Mar. 28, 2007, Magnetic Resonance Imaging (MRI) scans of women who were diagnosed with cancer in one…
On Nov. 16, 2006, the U.S. Food and Drug Administration (FDA) approved Genentech’s trastuzumab (Herceptin) for use with…
On Sept. 1, 2006, National Cancer Institute (NCI) researchers developed a new model for estimating the 5-year risk…
On May 23, 2006, the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, was launched to examine…
On Apr. 17, 2006, the National Cancer Institute (NCI) announced initial results of the Study of Tamoxifen and…
On Dec. 7, 2005, results from several studies presented at the San Antonio Breast Cancer Symposium validated that…
On Nov. 11, 2005, the U.S. Congress authorized the 2-year extension of Postage Stamp for Breast Cancer Research…
On Sept. 16, 2005, preliminary results from a large, clinical trial of digital vs. film mammography showed no…
On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…